BioCentury
ARTICLE | Clinical News

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

January 23, 2018 10:32 PM UTC

ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of 29% in a Phase Ib trial to treat advanced non-resectable pancreatic cancer. The company will present the data on Friday at the American Society of Clinical Oncology-Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium in San Francisco.

The open-label study enrolled 50 patients with locally advanced or metastatic pancreatic cancer. ChemoCentryx compared the survival result to a 2011 study which showed that FOLFIRINOX alone led to an 18-month OS rate of 18.6%. The historical study enrolled 342 patients with metastatic cancer only...